Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BPN-14967 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (fasted condition) | EXPERIMENTAL | 10 mg BPN-14967 or placebo |
| Cohort 2 (fasted condition) | EXPERIMENTAL | 25 mg BPN-14967 or placebo |
| Cohort 3 (fasted condition) | EXPERIMENTAL | 50 mg BPN-14967 or placebo |
| Cohort 4 (fed condition) | EXPERIMENTAL | 10 mg BPN-14967 or placebo |
| Cohort 5 (high-fat fed condition) | EXPERIMENTAL | 10 mg BPN-14967 or placebo |
| Name | Type | Description |
|---|---|---|
| BPN-14967 | DRUG | BPN-14967 oral capsules |
| Placebo | DRUG | Oral capsules |
Inclusion Criteria: * The subject is male or female (not of childbearing potential), 18 to 65 years of age, inclusive, at screening. * The subject voluntarily consents to participate in this study and * provides written informed consent before the start of any study-specific procedures. * The subje...
BPN-14967 is an investigational small molecule therapeutic being developed by Belite Bio, Inc. It has been studied in a Phase 1 clinical trial in healthy adult volunteers. The specific disease indications for which BPN-14967 is being developed have not been publicly disclosed.
BPN-14967 is being developed by Belite Bio, Inc., which trades on the Nasdaq under the ticker symbol BLTE. The company is the sponsor of the clinical program evaluating this small molecule therapeutic candidate.
BPN-14967 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The program remains investigational and has not been approved by the FDA for any indication.
BPN-14967 has been evaluated in one clinical trial: NCT04005807, titled "Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults." This completed Phase 1 study enrolled 40 healthy volunteers in the United States and used a randomized, double-blind, controlled design.
The Phase 1 trial NCT04005807 evaluated escalating doses of BPN-14967 in 40 healthy adult volunteers in the United States. It was a randomized, double-blind, controlled study. The trial has been completed and assessed safety and tolerability in participants aged 18 years and older.